126 related articles for article (PubMed ID: 32364270)
21. Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
Faehling M; Achenbach J; Staib P; Steffen U; Tessen HW; Gaillard VE; Brugger W
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1375-1383. PubMed ID: 29687154
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.
Dasanu CA; Alvarez-Argote J; Lippman SM; Plaxe SC
J Oncol Pharm Pract; 2018 Apr; 24(3):229-231. PubMed ID: 28436313
[TBL] [Abstract][Full Text] [Related]
23. Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Germonpré P; Van den Wyngaert T
PLoS One; 2019; 14(4):e0215135. PubMed ID: 30973926
[TBL] [Abstract][Full Text] [Related]
24. Necrolytic migratory erythema-like eruption associated with erlotinib in a patient with lung adenocarcinoma.
Ma SH; Li CY
Lung Cancer; 2020 Oct; 148():173-174. PubMed ID: 32773208
[No Abstract] [Full Text] [Related]
25. Anti-mitochondria antibody-related tubulointerstitial nephritis accompanied by severe hypokalemic paralysis.
Morita M; Yamaguchi Y; Masuyama S; Nakamura J; Kajimoto S; Haga R; Yamanouchi Y; Nagatoya K; Miwa H; Yamauchi A
CEN Case Rep; 2019 May; 8(2):119-124. PubMed ID: 30637665
[TBL] [Abstract][Full Text] [Related]
26. Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
Jakubowski CD; Plodkowski AJ; Chang JC; Rekhtman N; Iqbal A; Paik PK; Yu HA
Clin Lung Cancer; 2017 Jan; 18(1):e81-e83. PubMed ID: 27863924
[No Abstract] [Full Text] [Related]
27. Concomitant Acute Tubular Necrosis and Acute Interstitial Nephritis Induced by Tipifarnib in a Patient with Squamous Cell Carcinoma of the Lung.
Martinez de la Cruz P; Shabaka A; Mielgo-Rubio X; Guerrero-Marquez C; Gimenez-Moyano S; Fernandez-Juarez G
Am J Med Sci; 2021 Jul; 362(1):99-102. PubMed ID: 33872582
[TBL] [Abstract][Full Text] [Related]
28. [Nephrotoxin-induced tubulointerstitial nephropathies].
Kliem V; Lonnemann G; Brunkhorst R
Internist (Berl); 1996 Nov; 37(11):1116-28. PubMed ID: 9036107
[No Abstract] [Full Text] [Related]
29. Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis.
Kau HC; Tsai CC
Cutan Ocul Toxicol; 2016 Sep; 35(3):257-9. PubMed ID: 26340340
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
31. Hepatoid adenocarcinoma of the lung.
Qian GQ; Yin FY; Li GX; Chu JG
QJM; 2016 Sep; 109(9):619-20. PubMed ID: 27433025
[No Abstract] [Full Text] [Related]
32. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
33. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous cytomegalovirus (CMV) infection in a patient with metastasized lung cancer.
Lee CN; Po-Chao Chiu F; Hsu CK
Clin Microbiol Infect; 2021 Apr; 27(4):565-567. PubMed ID: 33524588
[TBL] [Abstract][Full Text] [Related]
35. Tubulointerstitial nephritis and uveitis syndrome: sore eyes and sick kidneys.
Lim AK; Roberts MA; Lim Joon T; Levidiotis V
Med J Aust; 2005 Nov; 183(9):477-8. PubMed ID: 16274351
[No Abstract] [Full Text] [Related]
36. [A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Tanaka H; Inomata M; Hayashi R; Shimokawa K; Tokui K; Okazawa S; Kambara K; Yamada T; Miwa T; Kashii T; Konishi H; Tobe K
Gan To Kagaku Ryoho; 2017 Jul; 44(7):595-597. PubMed ID: 28790264
[TBL] [Abstract][Full Text] [Related]
37. Complete remission of membranous nephropathy in a patient with lung adenocarcinoma treated with erlotinib.
Liu X; Bai Y; Zhou X; Gu X; Zhao L
J Clin Pharm Ther; 2020 Apr; 45(2):388-393. PubMed ID: 31730733
[TBL] [Abstract][Full Text] [Related]
38. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
39. CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs).
Ravanelli M; Agazzi GM; Ganeshan B; Roca E; Tononcelli E; Bettoni V; Caprioli A; Borghesi A; Berruti A; Maroldi R; Farina D
Eur J Radiol; 2018 Dec; 109():130-135. PubMed ID: 30527295
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
